Shusen Wang

6.4k total citations · 1 hit paper
128 papers, 2.5k citations indexed

About

Shusen Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shusen Wang has authored 128 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 35 papers in Cancer Research. Recurrent topics in Shusen Wang's work include HER2/EGFR in Cancer Research (49 papers), Advanced Breast Cancer Therapies (48 papers) and Cancer Treatment and Pharmacology (34 papers). Shusen Wang is often cited by papers focused on HER2/EGFR in Cancer Research (49 papers), Advanced Breast Cancer Therapies (48 papers) and Cancer Treatment and Pharmacology (34 papers). Shusen Wang collaborates with scholars based in China, United States and South Korea. Shusen Wang's co-authors include Zhongyu Yuan, Roujun Peng, Zhongsheng Tong, Tao Qin, Cong Xue, Rongzhen Luo, Zefei Jiang, Yanxia Shi, Hao Yu and Jiehua He and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Medicine and Nature Communications.

In The Last Decade

Shusen Wang

117 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Shusen Wang

Since Specialization

Citations

This map shows the geographic impact of Shusen Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shusen Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shusen Wang more than expected).

Fields of papers citing papers by Shusen Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shusen Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shusen Wang. The network helps show where Shusen Wang may publish in the future.

Co-authorship network of co-authors of Shusen Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Shusen Wang. A scholar is included among the top collaborators of Shusen Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shusen Wang. Shusen Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial breakdown → 2025 ·Nature Medicine ·Yongmei Yin, Ying Fan, (unknown), (unknown), Xiaojia Wang, Wěi Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, (unknown), (unknown), Zhongsheng Tong, (unknown), (unknown), Xiaoping Jin, (unknown), (unknown), Binghe Xu	16
2	Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial 2025 ·Nature Communications ·Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, (unknown), Xinlan Liu, (unknown), Bing Zhao, Shusen Wang, Xiaohua Zeng, (unknown), (unknown), Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, (unknown), Deyong Zhang, Tong Li	2
3	Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer 2024 ·The Breast ·Qianyi Lu, (unknown), Jianwei Zhang, (unknown), Limin Chen, Ruoxi Hong, Kuikui Jiang, Fei Xu, Wen Xia, (unknown), Jingmin Zhang, Kang Shao, Peng Sun, Shusen Wang	1
4	Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: A real-world retrospective study 2024 ·International Immunopharmacology ·Limin Chen, (unknown), Huailiang Wu, Qianyi Lu, Jiajia Huang, Shusen Wang	0
5	Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. 2024 ·Journal of Clinical Oncology ·Sònia Pernas, Seock‐Ah Im, Masaya Hattori, Binghe Xu, Shusen Wang, Yen‐Shen Lu, Giuliano Borges, Junji Tsurutani, Komal Jhaveri, Qingyuan Zhang, Michelino De Laurentiis, Noelia Martínez-Jáñez, Erika Hamilton, Hope S. Rugo, Kevin Kalinsky, Sara M. Tolaney, Lei Shi, (unknown), (unknown), Aditya Bardia	1
6	Construction of immune score and its prognostic value in invasive lobular carcinoma of the breast using computational pathology analysis 2023 ·Cancer Medicine ·Liye Wang, Peng Sun, (unknown), Qiufan Zheng, Kuikui Jiang, Ruoxi Hong, Shusen Wang	1
7	The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer 2023 ·npj Breast Cancer ·(unknown), Mei Li, (unknown), Qianyi Lu, Jia Fu, Kuikui Jiang, Ruoxi Hong, Shusen Wang, Fei Xu	0
8	Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors 2023 ·Journal of Personalized Medicine ·Kuikui Jiang, (unknown), Ruoxi Hong, Qianyi Lu, Fei Xu, Wen Xia, Qiufan Zheng, Shusen Wang	0
9	A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments 2023 ·International Journal of Cancer ·Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wěi Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, (unknown), Xiuyu Julie Cong, (unknown)	27
10	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study 2021 ·Cancer Communications ·Ruoxi Hong, Wen Xia, Liye Wang, (unknown), Qianyi Lu, Kuikui Jiang, Shengfeng Li, Jin‐Quan Yu, (unknown), (unknown), (unknown), Xin An, Jiajia Huang, Cong Xue, Xiwen Bi, Yanxia Shi, Zhongyu Yuan, Fei Xu, Shusen Wang	23
11	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial 2021 ·BioDrugs ·Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng, Xichun Hu, Igor Bondarenko, Hryhoriy Adamchuk, Liangming Zhang, Dmytro Trukhin, Shusen Wang, Hong Zheng, Zhongsheng Tong, Yaroslav Shparyk, Qingyu Wang, (unknown)	28
12	Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center 2020 ·Cancer Communications ·Qianyi Lu, (unknown), Fei Xu, Wen Xia, Qiufan Zheng, Ruoxi Hong, Kuikui Jiang, (unknown), Yuan Li, Yanxia Shi, Zhongyu Yuan, Shusen Wang	15
13	Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress 2020 ·Expert Review of Anticancer Therapy ·Binghe Xu, Tao Sun, Shusen Wang, Yingcheng Lin	15
14	Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer 2020 ·The Oncologist ·Xinyue Wang, Jibin Li, Wei Shi, (unknown), Wen Xia, Jiajia Huang, Yanhong Su, Shusen Wang, Yanxia Shi, Xiwen Bi, Zhongyu Yuan	5
15	Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes 2019 ·Cancer Medicine ·Jiayu Wang, (unknown), Yujian Shi, (unknown), Tao Sun, Lili Tang, Qing Lü, (unknown), Ning Liao, Feng Jin, (unknown), Tao Huang, Jun Qian, Danmei Pang, Shusen Wang, (unknown), Xinhong Wu, Ying Lin, Haiyan Qin, Binghe Xu	17
16	Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study 2019 ·Journal of Clinical Oncology ·Fei Ma, Quchang Ouyang, Wěi Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li, Shiying Yu, Jifeng Feng, Shusen Wang, Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu	247
17	Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma 2018 ·Clinical Cancer Research ·Yihebali Chi, Zhiwei Fang, Xiaonan Hong, Yang Yao, Ping Sun, Guowen Wang, Feng Du, Yongkun Sun, Qiong Wu, Guofan Qu, Shusen Wang, Jianmin Song, Jianchun Yu, Yongkui Lu, Xia Zhu, Xiaohui Niu, Zhiyong He, Jinwan Wang, Hao Yu, Jianqiang Cai	245
18	Clinical implication of platelet-lymphocyte ratio and PD-L1 in breast cancer patients 2018 ·Translational Cancer Research ·Qianyi Lu, Tao Qin, Fei Xu, (unknown), Wen Xia, Qiufan Zheng, (unknown), Kai Zhang, Ge Qin, (unknown), Ruoxi Hong, (unknown), Zhongyu Yuan, Shusen Wang	1
19	Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray 2011 ·Medical Oncology ·Jiehua He, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, Gui‐Nan Lin, Xiaomei Jiang, Tao Qin	137
20	Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer 2011 ·Medical Oncology ·Yanxia Shi, Yuting Tan, Zhongyu Yuan, Shusen Wang, Roujun Peng, Xin An, Ye Cao, Ying Jin, Xiuyu Cai, Yue-Li Sun, Xiaoyu Teng, Donggeng Liu	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact